



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
www.uspto.gov

Stephen F. Weinstock  
Abbott Laboratories  
Dept. 377, Bldg. AP6A-1  
100 Abbott Park Road  
Abbott Park IL 60064-6008

In Re: Patent Term Extension  
Application for  
U.S. Patent No. 6,090,382

MAILED

JAN 26 2007

CENTRAL REEXAMINATION UNIT

NOTICE OF FINAL DETERMINATION

A determination has been made that U.S. Patent No. 6,090,382, which claims the human biological product HUMIRA® (adalimumab), is eligible for patent term extension under 35 U.S.C. § 156. The period of extension has been determined to be 326 days.

A single request for reconsideration of this final determination as to the length of extension of the term of the patent may be made if filed within one month of the date of this notice. Extensions of time under 37 CFR § 1.136(a) are not applicable to this time period. In the absence of such request for reconsideration, the Director will issue a certificate of extension, under seal, for a period of 326 days.

The period of extension, if calculated using the Food and Drug Administration determination of the length of the regulatory review period published in the Federal Register of February 1, 2006, (71 Fed. Reg. 5342), would be 588 days. Under 35 U.S.C. § 156(c):

$$\begin{aligned}\text{Period of Extension} &= \frac{1}{2} (\text{Testing Phase}) + \text{Approval Phase} \\ &= \frac{1}{2} (1,443 - 825) + 279 \\ &= 588 \text{ days (1.6 years)}\end{aligned}$$

Since the regulatory review period began April 16, 1998, before the patent issued (July 18, 2000), only that portion of the regulatory review period occurring after the date the patent issued has been considered in the above determination of the length of the extension period 35 U.S.C. § 156(c). (From April 16, 1998, to and including, July 18, 2000, is 825 days; this period is subtracted for the number of days occurring in the testing phase according to the FDA determination of the length of the regulatory review period.) No determination of a lack of due diligence under 35 U.S.C. § 156(c)(1) was made.

However, the 14 year exception of 35 U.S.C. § 156(c)(3) operates to limit the term of the extension in the present situation because it provides that the period remaining in the term of the patent measured from the date of approval of the approved product plus any patent term extension cannot exceed fourteen years. The period of extension calculated above, 588 days, would extend the patent from February 9, 2016 to September 19, 2017, which is beyond the 14-year limit (the approval date is December 31, 2002, thus the 14 year limit is December 31, 2016). The period of extension is thus limited to 326 days, by operation of 35 U.S.C. § 156(c)(3). Accordingly, the period of extension is the number of days to extend the term of the patent from its original expiration date, February 9, 2016, to and including, December 31, 2016, or 326 days.

The limitations of 35 U.S.C. 156(g)(6) do not operate to further reduce the period of extension determined above.

Upon issuance of the certificate of extension, the following information will be published in the Official Gazette:


U.S. Patent No.: 6,090,382

Granted: July 18, 2000  
Original Expiration Date<sup>1</sup>: February 9, 2016  
Applicant: Jochen G. Salfeld et al.  
Owner of Record: Abbott Biotechnology, Ltd.  
Title: Human Antibodies That Bind Human TNF $\alpha$   
Product Trade Name: HUMIRA® (adalimumab)  
Term Extended: 326 days  
Expiration Date of Extension: December 31, 2016

Any correspondence with respect to this matter should be addressed as follows:

By mail: Mail Stop Hatch-Waxman PTE      By FAX: (571) 273-7755  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450.

Telephone inquiries related to this determination should be directed to the undersigned at (571) 272-7755.



Mary C. Till  
Legal Advisor  
Office of Patent Legal Administration  
Office of the Deputy Commissioner  
for Patent Examination Policy

cc: Office of Regulatory Policy  
HFD - 7  
5600 Fishers Lane (Rockwall II Rm. 1101)  
Rockville, MD 20857

Attention: Beverly Friedman

RE: HUMIRA® (adalimumab)  
FDA Docket No.: 2004E-0445

---

<sup>1</sup>Subject to the provisions of 35 U.S.C. § 41(b).